1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Wockhardt’s UK Business Grows But Other Markets Underperform

Company Sees Major Growth Come From COVID-19 Vaccine Business

 
• By Akriti Seth

Wockhardt has seen a good financial fourth quarter and full year for its UK business, which contributed 41% of the company’s global revenue in Q4 FY21 and 37% to its global revenue for the financial year thanks to its COVID-19 vaccine business. However, the company’s US, India, Ireland and emerging markets businesses delivered a weak fourth quarter.

UK GBP
Wockhardt’s UK business sees a 14% growth in quarterly sales and 13% growth in annual sales • Source: Alamy

Wockhardt Limited has enjoyed significant growth in its UK business, reporting an increase of 14% in sales to INR2.61bn ($35.7m) for the firm’s financial fourth quarter ended 31 March 2021. The company also saw an annual growth of 13% in UK sales, clocking in INR10.13bn for FY21.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.

Samsung Bioepis Grows After US Launches

 
• By Dave Wallace

Samsung Bioepis has revealed first-quarter figures that reflect recent launches driving growth for the Korean biosimilars developer.

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.